` GRI (GRI Bio Inc) vs S&P 500 Comparison - Alpha Spread

GRI
vs
S&P 500

Over the past 12 months, GRI has underperformed S&P 500, delivering a return of -92% compared to the S&P 500's +14% growth.

Stocks Performance
GRI vs S&P 500

Loading
GRI
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
GRI vs S&P 500

Loading
GRI
S&P 500
Difference
www.alphaspread.com

Performance By Year
GRI vs S&P 500

Loading
GRI
S&P 500
Add Stock

Competitors Performance
GRI Bio Inc vs Peers

GRI Bio Inc
Glance View

Market Cap
4.7m USD
Industry
Pharmaceuticals

GRI Bio Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in La Jolla, California and currently employs 2 full-time employees. The company went IPO on 2021-02-10. GRI Bio, Inc. is a clinical-stage biotechnology company. The firm is focused on advancing a pipeline of Natural Killer T (NKT) modulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseases. The firm's lead program, GRI-0621 is a small molecule RAR-beta dual agonist that inhibits the activity of human Type I, or invariant, NKT (iNKT) cells, which is being developed for the treatment of Idiopathic pulmonary fibrosis (IPF). GRI-0621 is a once-daily oral capsule for several fibrotic indications. The Company’s second asset GRI-0803, is a novel activator of human Type 2 NKT cells in development for the treatment of autoimmune disorders, with an initial focus on systemic lupus erythematosus. Additionally, the Company has a library of 500+ proprietary compounds targeting a number of high value indications with unmet need.

GRI Intrinsic Value
2.14 USD
Undervaluation 7%
Intrinsic Value
Price
Back to Top